When more than 200 million first-time restricted shares were released, Huada Gene was reported by real name. Despite its strong denial, as of June 27, the stock price was 101.29 yuan, a drop of 8.28%. Closed on December 29, 2017. Compared with the price of 207.53 yuan, the stock price of Huada Gene has been shackled for half a year.
On June 27, the Changjiang Commercial Daily reporter called Huada Gene. The company’s secretary-general office replied that the above statement was issued by the group, but the day still affected the joint stock company, and the follow-up joint stock company will issue another clarification announcement, all to clarify The announcement shall prevail.
Previously, Nanjing Changjian Yujia Health Management Co., Ltd. (hereinafter referred to as “Nanchang Changjian”) reported to the Jiangsu Provincial People’s Government on a real-name basis that Huada’s pseudo-tech high-tech hijacked the fraud, was suspected of bribing officials, and used land resources and government finances. Subsidies, etc.. Huada Gene issued a clarification statement, saying that the Internet article mentions that the company 'cheats state-owned assets' and other claims are completely nonsense.
The Changjiang Business Daily reporter sorted out the Huada Genes 2017 financial report and found that its R&D investment in 2017 was 174 million yuan, a year-on-year decrease of 1.36%. 2016-2017, accumulated R&D expenditures for two years was 351 million yuan, less than two years accumulated sales expenses Half of 730 million yuan.
In addition, the announcement shows that from 2014 to 2017, the original value of the three-year intangible assets of Huada Gene has remained almost unchanged, which means that there are no new patents in its four years.
Reported by real name before the release of the flood peak
Recently, it was reported by Nanjing Changjian real name, saying that Huada Gene defrauded land resources and government financial subsidies. On the morning of the 27th, Huada Gene issued a statement on the above report saying that there is no 'National Gene Bank Cell Center Jiangsu Operation Center' Named institutions, private non-enterprise units or other independent social organizations. Nanjing Changjian Yujia has failed to fulfill its main contractual obligations and has dissolved all cooperation with Shenzhen Huada Life Science Research Institute. During the period of termination of the contract, Nanjing Chang Jian continues to make a living, and many Huada employees are harassed and even threatened.
In addition, Huada Gene said that it has not participated in any real estate projects in Jiangsu and has not obtained land resources. The Huada gene mentioned in the article defrauds state-owned assets, the slanders of Chairman Wang Jian and the past cooperation of Huada Gene. 4. The personal attack and revenge of a partner is purely nonsense and malicious.
BGI said it has taken legal actions to pursue its legal responsibilities.
In response, the Office of the Board of Directors of Huada Gene replied that the above statement was issued by the group, but it still affects the joint stock company on the same day. The follow-up joint stock company will issue another clarification announcement, which is subject to the clarification announcement.
In 2017, R&D investment reached 174 million, a year-on-year decrease of 1.36%
Since the beginning of the listing, the noise of BGI has continued. It stated in the announcement that the company has focused on research and development of new service types in order to consolidate and enhance its core competitiveness. In the last two years (2016-2017), the company’s R&D investment accounted for sales. The proportion of income is above 8%.
However, BGI 2017 financial results, BGI 2017 R & D investment of 1.74 billion yuan, down 1.36% year on year data show that in 2016 - 2017, BGI three years of research and development expenditures were 1.77 billion yuan and 1.74 Billion yuan, R&D expenditures for two years totaled 351 million yuan. During the same period, the gene sales costs of Huada were 328 million yuan, 402 million yuan, and cumulative expenses were 730 million yuan. The two-year R&D expenditure is less than half of the sales cost.
According to the 2017 annual report, as of the end of the reporting period, the company and its wholly-owned, holding subsidiaries owned 282 authorized patents, including 263 invention patents, 10 utility model patents, and 9 design patents; 366 items. The core technology patent covers all key technical aspects such as experimental instruments, sample processing, sequencing library construction, quality control, and biological information analysis. Among them, the company's bioinformatics analysis has obtained 460 software copyrights, and its technical advantages are obvious. .
Compared with the foreign genetic industry, there is still a gap between the above data. In the case of the American company Illumina, in 2017, its R&D investment reached US$546 million, and R&D investment accounted for 19.84%. From the number of patents, Illumina's application in 2017 is 240, and Huada Gene has only 8 patent applications in 2017.
The original book value of intangible assets has hardly changed for 4 years
In the Huada Gene Prospectus, the original value of intangible assets from 2014 to 2017 has hardly changed.
The data shows that the original book value of intangible assets in 2014-2017 was 222 million yuan, 225.1 million yuan, 225.3 million yuan and 232 million yuan.
The original value of the account refers to a value statistic based on software, patents and non-patented technology. If the change of data is not large, it means that in the past few years, the company has almost no new research patents.
From the perspective of the number of R&D personnel, although the number has continued to increase each year in recent years, there is still a gap compared with peers. In addition, in the 2017 Annual Report, BGI’s gene disclosure still has patent infringement issues. This includes its subsidiary Hong Kong’s medical patent infringement. , The final payment to the plaintiff in 2017 was less than 3% of the company's total profit in 2017 and 2018-2021 is expected to pay the plaintiff’s costs annually less than 1% of the company’s total profit in 2017 and Aston Genes, Hong Kong Chinese The university signed a settlement agreement.